McKesson (NYSE:MCK) issued an update on its FY19 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $13.00 -13.80 for the period, compared to the Thomson Reuters consensus estimate of $13.37. McKesson also updated its FY18 guidance to $12.50 -12.80 EPS.
Shares of MCK traded up $2.82 during trading hours on Wednesday, hitting $151.71. 1,465,999 shares of the stock were exchanged, compared to its average volume of 1,746,240. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.61 and a current ratio of 1.07. McKesson has a 12-month low of $134.25 and a 12-month high of $178.86. The stock has a market capitalization of $30,606.31, a price-to-earnings ratio of 13.07, a PEG ratio of 1.36 and a beta of 1.32.
McKesson (NYSE:MCK) last issued its quarterly earnings results on Thursday, February 1st. The company reported $3.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.92 by $0.49. McKesson had a return on equity of 22.98% and a net margin of 2.34%. The firm had revenue of $53.62 billion during the quarter, compared to analysts’ expectations of $51.98 billion. During the same period in the previous year, the business earned $3.04 earnings per share. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. analysts predict that McKesson will post 12.69 earnings per share for the current year.
Several analysts recently commented on MCK shares. Credit Suisse Group reiterated a sell rating and set a $130.00 price target on shares of McKesson in a research report on Friday, February 2nd. Jefferies Group upgraded McKesson from a hold rating to a buy rating and set a $205.00 price target for the company in a research report on Wednesday, January 24th. ValuEngine cut McKesson from a buy rating to a hold rating in a research report on Sunday, December 31st. Zacks Investment Research upgraded McKesson from a hold rating to a buy rating and set a $189.00 price target for the company in a research report on Friday, February 2nd. Finally, Needham & Company LLC boosted their price target on McKesson from $173.00 to $180.00 and gave the stock a buy rating in a research report on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. McKesson has a consensus rating of Hold and a consensus price target of $176.32.
In other McKesson news, SVP Erin M. Lampert sold 1,413 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $149.38, for a total value of $211,073.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3388964/mckesson-mck-releases-fy19-earnings-guidance.html.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. The company operates in two segments, McKesson Distribution Solutions and McKesson Technology Solutions. The McKesson Distribution Solutions segment distributes branded and generic pharmaceutical drugs, and other healthcare-related products; and provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.